Why the study?
Does intravenous levosimendan provide sustained hemodynamic effects?
Does intravenous levosimendan provide sustained hemodynamic effects?
Intravenous levosimendan provides sustained hemodynamic effects even after discontinuation, likely mediated by its active metabolite OR-1896.
Supports shorter levosimendan infusions for sustained benefit in acute HF; extends RCT evidence on OR-1896 persistence.
The hemodynamic effects of Levo were maintained during a 48-hour continuous infusion and for at least 24 hours after discontinuation of a 24-hour infusion. The active metabolite OR-1896 increased for at least 24 hours after cessation of drug infusion and may account for the prolonged hemodynamic effects of Levo.
No takes yet. Share an insight, caveat, or question.
Kivikko et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: